These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 2548206)

  • 1. Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone.
    Bajusz S; Janaky T; Csernus VJ; Bokser L; Fekete M; Srkalovic G; Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1989 Aug; 86(16):6313-7. PubMed ID: 2548206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly potent analogues of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6.
    Bajusz S; Janaky T; Csernus VJ; Bokser L; Fekete M; Srkalovic G; Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1989 Aug; 86(16):6318-22. PubMed ID: 2548207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups.
    Janáky T; Juhász A; Bajusz S; Csernus V; Srkalovic G; Bokser L; Milovanovic S; Redding TW; Rékási Z; Nagy A
    Proc Natl Acad Sci U S A; 1992 Feb; 89(3):972-6. PubMed ID: 1310542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.
    Nagy A; Schally AV; Armatis P; Szepeshazi K; Halmos G; Kovacs M; Zarandi M; Groot K; Miyazaki M; Jungwirth A; Horvath J
    Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7269-73. PubMed ID: 8692981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties.
    Janáky T; Juhász A; Rékási Z; Serfözö P; Pinski J; Bokser L; Srkalovic G; Milovanovic S; Redding TW; Halmos G
    Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10203-7. PubMed ID: 1332035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of biological activities of new LH-RH antagonists (T-series) in male and female rats.
    Pinski J; Yano T; Janaky T; Nagy A; Juhasz A; Bokser L; Groot K; Schally AV
    Int J Pept Protein Res; 1993 Jan; 41(1):66-73. PubMed ID: 8436447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of proline in position 3 for potent inhibition of the activity of the luteinizing hormone releasing hormone and of ovulation.
    Humphries J; Wan YP; Folkers K; Bowers CY
    Biochem Biophys Res Commun; 1976 Oct; 72(3):939-44. PubMed ID: 791291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural requirements in positions 1, 2, 3, and 6 of the luteinizing hormone-releasing hormone (LH-RH) for antiovulatory activity.
    Humphries J; Wan YP; Wasiak T; Folkers K; Bowers CY
    J Med Chem; 1979 Jul; 22(7):774-7. PubMed ID: 376847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues.
    Bajusz S; Csernus VJ; Janaky T; Bokser L; Fekete M; Schally AV
    Int J Pept Protein Res; 1988 Dec; 32(6):425-35. PubMed ID: 2469662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects.
    Bajusz S; Kovacs M; Gazdag M; Bokser L; Karashima T; Csernus VJ; Janaky T; Guoth J; Schally AV
    Proc Natl Acad Sci U S A; 1988 Mar; 85(5):1637-41. PubMed ID: 3278323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells.
    Segal-Abramson T; Kitroser H; Levy J; Schally AV; Sharoni Y
    Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2336-9. PubMed ID: 1312718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75).
    Bokser L; Srkalovic G; Szepeshazi K; Schally AV
    Neuroendocrinology; 1991 Aug; 54(2):136-45. PubMed ID: 1662786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory analogues of the luteinizing hormone-releasing hormone having D-aromatic residues in positions 2 and 6 and variation in position 3.
    Humphries J; Wan YP; Folkers K; Bowers CY
    J Med Chem; 1978 Jan; 21(1):120-3. PubMed ID: 338902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luteinizing hormone-releasing hormone antagonists containing very hydrophobic amino acids.
    Nestor JJ; Tahilramani R; Ho TL; McRae GI; Vickery BH
    J Med Chem; 1984 Sep; 27(9):1170-4. PubMed ID: 6381733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the in vitro and in vivo activity of the L-, D,L- and D-Cit6 forms of the LH-RH antagonist Cetrorelix (SB-75).
    Pinski J; Schally AV; Yano T; Groot K; Srkalovic G; Serfozo P; Reissmann T; Bernd M; Deger W; Kutscher B
    Int J Pept Protein Res; 1995 May; 45(5):410-7. PubMed ID: 7591480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent pituitary-gonadal axis suppression and extremely low anaphylactoid activity of a new gonadotropin releasing hormone (GnRH) receptor antagonist "azaline B".
    Campen CA; Lai MT; Kraft P; Kirchner T; Phillips A; Hahn DW; Rivier J
    Biochem Pharmacol; 1995 May; 49(9):1313-21. PubMed ID: 7763313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonapeptide ethylamide inhibitors of the luteinizing hormone-releasing hormone (LH-RH) having a D-alanyl residue in position 6 and variations at positions 2 and 3.
    Humphries J; Wan YP; Folkers K; Bowers C
    J Med Chem; 1977 Dec; 20(12):1674-7. PubMed ID: 338901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active reduced-size hexapeptide analogues of luteinizing hormone-releasing hormone.
    Haviv F; Palabrica CA; Bush EN; Diaz G; Johnson ES; Love S; Greer J
    J Med Chem; 1989 Oct; 32(10):2340-4. PubMed ID: 2552116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists.
    Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
    Cancer Res; 1990 Jun; 50(12):3716-21. PubMed ID: 2160323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
    Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
    Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.